Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
Phase 2
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Registration Number
- NCT00097331
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 261
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of new gadolinium-enhancing lesions on monthly MRI scans
- Secondary Outcome Measures
Name Time Method Expanded Disability Status Scale (EDSS) and MS Functional Composite (MSFC) Number of other lesion types on MRI Number of relapses during treatment Circulating lymphocyte and neutrophil counts Health Outcomes: MSIS-29, Employment status
Trial Locations
- Locations (1)
GSK Investigational Site
🇪🇸Malaga, Spain